These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27578253)

  • 1. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
    Matos I; Elez E; Capdevila J; Tabernero J
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
    Lee YC; Michael M; Zalcberg JR
    Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
    Riesco-Martinez MC; Sanchez-Torre A; Garcia-Carbonero R
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1295-1305. PubMed ID: 28965421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
    Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E
    Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
    Lee CC; Shiao HY; Wang WC; Hsieh HP
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
    Kircher SM; Nimeiri HS; Benson AB
    Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
    Sola AM; Johnson DE; Grandis JR
    Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
    Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V
    Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future targets and therapies in metastatic colorectal cancer.
    Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
    J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging tyrosine kinase inhibitors for head and neck cancer.
    Bossi P; Locati L; Licitra L
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):445-59. PubMed ID: 24094093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.
    Akil H; Perraud A; Jauberteau MO; Mathonnet M
    World J Gastroenterol; 2016 Jan; 22(2):490-500. PubMed ID: 26811602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
    Karasic TB; Rosen MA; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):661-671. PubMed ID: 28721456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.